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Abstract Targeting gene therapy vectors to abundant receptors
on airway epithelia may allow a significant enhancement of gene
delivery and thereby be of particular importance for the gene
therapy of cystic fibrosis. K9L1-Integrins are highly expressed
throughout the human airway epithelia in vivo, irrespective of
any particular clinical status. Aiming to improve the targeting of
our non-viral integrin-mediated gene transfer systems to airway
epithelia, we searched for a short tenascin C-derived peptide
which would bind to these integrins. By utilizing recombinant
bacteriophages that display overlapping regions of the third
fibronectin type III repeat of tenascin C (TNfn3), we were able to
localize its K9L1-integrin binding site to the B-C loop of TNfn3.
A synthetic Pro-Leu-Ala-Glu-Ile-Asp-Gly-Ile-Glu-Leu-Thr-Tyr
peptide (PLAEIDGIELTY) was shown to displace K9L1-
integrin-expressing cells completely from binding to TNfn3.
This peptide, therefore, may prove useful both for the examina-
tion of the functional importance of K9L1-integrins in vivo and
the development of gene therapy vectors or drugs targeting these
integrins.
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1. Introduction
The recent cystic ¢brosis gene therapy trials applying lip-
osomes or adenoviral vectors to airway epithelia have shown
that neither the degree nor the duration of corrective e¡ects
are yet su⁄cient to bene¢t patients signi¢cantly (for review see
[1]). Current adenoviral gene therapy approaches depend on
the cellular expression of Kv-integrins [2] which are essential
for virus entry into the target cells through speci¢c interaction
with the arginine-glycine-aspartic acid (RGD) motif of the
adenovirus pentone base [3]. Lack of these integrins has
been suggested as the reason for the unexpectedly poor per-
formance of adenoviral vectors in recent clinical trials [4^6].
Therefore, the identi¢cation of novel ligands targeting abun-
dant receptors on airway epithelial cells may be crucial for
further progress in this ¢eld of gene therapy, in particular for
the development of targeted non-viral vector systems.
K9L1-Integrins are highly expressed throughout the human
airway epithelia (but not on alveolar epithelium) in vivo, irre-
spective of any particular clinical status [7]. They have also
been found in other tissues where the extracellular matrix
glycoprotein tenascin is present, such as the cornea [8] and
airway smooth muscle [9], as well as on the surface of cells
including hepatocytes which are not surrounded by tenascin
[10]. Tenascin C was identi¢ed as a speci¢c K9L1-integrin li-
gand and the binding activity could be localized to its third
¢bronectin type III repeat (TNfn3) [11]. More recently, the N-
terminal domain of osteopontin was shown to contain a cryp-
tic adhesive site recognized by K9L1-integrins, the sequence of
which has not been elucidated yet [12]. It is strongly suspected
that other ligands for this receptor also exist [13].
We have previously demonstrated that a cyclic RGD pep-
tide in fusion with oligo-L-lysine is capable of mediating DNA
transfer into a variety of cell types in culture [14,15]. We have
shown that gene delivery is mediated by integrins, namely the
¢bronectin and vitronectin receptors. However, as with ad-
enoviral gene delivery systems, our construct would prove
incapable of transferring DNA to cells which do not express
these receptors. This study, therefore, aimed to ¢nd a tenascin
C-derived peptide ligand binding to K9L1-integrins to improve
the targeting of our non-viral vectors to airway epithelia. By
combining phage display and competitive cell binding inhib-
ition approaches we identi¢ed a novel peptide, PLAEIDGI-
ELTY, as promising for the development of gene therapy
vectors or drugs targeting K9L1-integrins.
2. Materials and methods
2.1. Cell lines, bacterial strains and reagents
The human colon carcinoma cell line SW480, either mock-trans-
fected or stably expressing K9L1-integrins [11], was grown in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) containing 10% fetal calf
serum (FCS), penicillin (100 U/ml), streptomycin (100 U/ml) and
G418 (1 mg/ml). All tissue culture reagents were purchased from
Life Technologies, Paisley, UK.
The bacterial strain Escherichia coli TG1 was provided by Dr. Ri-
chard Perham (University of Cambridge, UK) and maintained on M9
minimal medium [16].
The pGEX plasmid expressing TNfn3/glutathione S-transferase fu-
sion proteins [17] was obtained from Dr. Kathryn L. Crossin (Scripps
Research Institute, La Jolla, CA, USA). Recombinant TNfn3 was
produced in E. coli and puri¢ed as described previously [18].
2.2. Oligonucleotides and peptides
Overlapping oligonucleotide pairs TEN1A (5P-TACATGC-
GGTGCACAGCCCGGGCGCTTGGATGCCCCCAGCCAGATC-
GAGGTGAAAGATGTCACAGACACCACTGCCTTGATCACCT-
G-3P) and TEN1B (5P-TCAGGAGCAGCGGCCGCCCCGGGG-
TAGGTCAGCTCAATGCCATCGATCTCAGCCAGGGGCTTGA-
ACCAGGTGATCAAGGCAGTGGTG-3P), TEN2A (5P-TACATG-
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CGGTGCACAGCCCGGGGAGATCGATGGCATTGAGCTGAC-
CTACGGCATCAAAGACGTGCCAGGAGACCGTACCACCAT-
CGA-3P) and TEN2B (5P-TCAGGAGCAGCGGCCGCCCCGGG-
CTTCAGGTTCCCGATGGAGTACTGGTTCTCGTCCTCTGTG-
AGATCGATGGTGGTACGGTCTCCT-3P), TEN3A (5P-TACATG-
CGGTGCACAGCCCGGGAACCAGTACTCCATCGGGAACCT-
GAAGCCTGACACTGAGTACGAGGTGTCCCTCATCTCCCGC-
AG-3P) and TEN3B (5P-TCAGGAGCAGCGGCCGCCCCGGG-
TGTTGTGAAGGTCTCTTTGGCTGGGTTGCTTGACATGTCA-
CCTCTGCGGGAGATGAGGGACACC-3P), derived from the
cDNA sequence of human tenascin C [19] (adaptor sequences ena-
bling insertion into fd-tet DNA underlined), were purchased from
Genosys Biotechnologies, Cambridge, UK. The primer 5P-
TGAATTTTCTGTATGAGG-3P was used for the sequencing of
gene III inserts of fd-tet DNA.
The peptides EIDGIEL, PLAEIDGIELTY, IAEYIPLGLETD and
KPLAEI were obtained from Genosys Biotechnologies, the peptide
GDLAIEEI was kindly provided by Dr. Nariaki Matsuura (Univer-
sity of Osaka, Japan).
2.3. DNA puri¢cation, restriction cleavage, ligation and sequencing
The replicating form phage DNA was puri¢ed using the QIAprep
spin plasmid kit (Qiagen, Crawley, UK), single-stranded DNA by
phenol extraction of a phage suspension followed by DNA precipita-
tion with ethanol according to [16]. Restriction cleavage of double-
stranded phage DNA, agarose gel electrophoresis and most of the
ligations were performed using standard protocols. All restriction en-
donucleases were products of New England Biolabs, Hitchin, UK. T4
DNA ligase was from Life Technologies. Puri¢cation of DNA frag-
ments after separation in an agarose gel was performed with the Qiaex
II kit (Qiagen). DNA sequencing was done with the T7 Sequenase 2.0
kit and [33P]dATP from Amersham, Bucks, according to the manu-
facturer’s instructions.
2.4. Construction of recombinant phages displaying overlapping parts of
TNfn3
The bacteriophage fd-tet which confers tetracycline resistance upon
transduced cells was a gift from Dr. John McCa¡erty (Cambridge
Antibody Technology, UK).
Oligonucleotide duplexes TEN1, TEN2 and TEN3 were obtained
by incubating the oligonucleotide pairs TEN1A/1B, TEN2A/2B and
TEN3A/3B, respectively, for 3 min at 90‡C, cooling to room temper-
ature within 10 min and ¢lling in using dNTPs and DNA polymerase
I large fragment (Boehringer Mannheim, Lewes, UK). The duplexes
were cleaved with the restriction endonucleases ApaLI and NotI, li-
gated separately with appropriately cleaved fd-tet DNA backbones
and cloned in Subcloning E⁄ciency DH5K competent cells (Life Tech-
nologies) on LB agar dishes containing 30 Wg tetracycline/ml LB me-
dium. The DNA sequence and correct insertion of each oligonucleo-
tide duplex were con¢rmed by sequencing of DNA from single
colonies. Phages were ampli¢ed in tetracycline-containing LB broth
inoculated with transduced bacteria as described in [20]. After pellet-
ing the bacterial cells by centrifugation and decanting the upper 80%
of the clari¢ed supernatant, phages were precipitated from the super-
natant according to [16]. The precipitate was resuspended in 1/100
supernatant volume of Tris-bu¡ered saline (50 mM Tris-HCl, pH
7.5, 150 mM NaCl). Insoluble material was removed by a further
centrifugation at 12 000Ug. The puri¢ed phage suspension was then
¢lter-sterilized and stored at 4‡C.
The expected fusion proteins were visualized on a SDS polyacryl-
amide gel and su⁄cient pIII function of all phage constructs was
demonstrated by transduction of E. coli TG1 cells.
2.5. Construction of a positive control phage
A positive control phage, encoding the whole TNfn3, was con-
structed using the oligonucleotide duplexes TEN1, TEN2 and
TEN3. TEN1 and TEN2 were joined at the common unique AluI
site and ligated with a fd-tet DNA backbone at ApaLI and BamHI
restriction sites in a three-fragment assembly ligation reaction. 1 Wg
DNA in a total volume of 10 Wl was used in this reaction with a molar
ratio of phage DNA to TEN1 and TEN2 of 1:5:5. The ligation
procedure comprising two temperature steps was performed as de-
scribed previously [21] and the resulting phage genome was cloned
in E. coli. The joined duplexes TEN1 and TEN 2 were then excised
from replicating form phage DNA with the endonucleases ApaLI and
ScaI, isolated from a 2.5% agarose gel and ligated with ScaI/BamHI-
cleaved TEN3 and ApaLI/BamHI-cleaved fd-tet DNA in another
three-fragment assembly ligation reaction followed by transformation
of Maximum E⁄ciency DH5K competent cells. The presence of the
entire TNfn3-DNA in the correct reading frame was established by
DNA sequencing. Phages containing the desired insert, named
fdTENC, were ampli¢ed and puri¢ed as described above, and the
retained pIII function was con¢rmed by transduction of E. coli
TG1 cells.
2.6. Phage quanti¢cation
The number of infectious fd phages was determined by addition of
10 Wl samples of 10-fold serial dilutions of the phage suspension in LB
to 1 ml of LB broth containing E. coli TG1 in mid-logarithmic phase
of growth and incubation for 30 min at 37‡C under gentle shaking.
100 Wl of each sample were spread on LB-tetracycline plates, and
tetracycline-resistant colonies were counted after incubation for 20 h
at 37‡C.
2.7. Screening of recombinant phages for binding to K9L1-integrin
The phages fdTENC, fdTEN1, fdTEN2, fdTEN3 and fd-tet were
tested separately on both mock-transfected and K9L1-integrin-express-
ing SW480 cells. The cells were harvested from 250 ml tissue culture
£asks (Corning) when subcon£uent by adding 2 mM EDTA in Dul-
becco’s phosphate-bu¡ered saline (PBS) and incubating for 20 min at
37‡C. Cells were washed with DMEM containing 10% FCS, and the
¢nal cell pellet was resuspended in DMEM containing FCS, penicillin/
streptomycin and G418. 4U105 cells/well were transferred to tissue
culture-treated 6 well plates and allowed to attach to the wells over-
night at 37‡C. Wells were washed with PBS on the following day and
then blocked with 1% fraction V bovine serum albumin (BSA) in
DMEM for 1 h at 37‡C. After discarding the blocking solution and
repeated washing with Tris-bu¡ered saline (TBS) containing 0.1% v/v
Tween-20, 1011 cfu of the individual phages each in 1 ml TBS con-
taining 0.1% v/v Tween-20 were added and the plates rocked gently
for 1 h at room temperature. Afterwards the phage solutions were
poured o¡ and the wells were washed thoroughly with TBS containing
0.2% v/v Tween-20. Bound phages were eluted with 1 ml 0.2 M gly-
cine-HCl, 0.1% BSA (pH 2.2) per well by gentle rocking for 10 min at
room temperature. The eluates were transferred to individual tubes
and neutralized each with 150 Wl 1 M Tris-HCl (pH 9.1). The number
of eluted phages/well was estimated by separate titering as described
above.
2.8. Competitive cell binding inhibition assays
Individual wells of non-tissue culture-treated polystyrene 96 well
£at bottom microtiter plates (Costar EIA/RIA 3590) were coated by
incubation with intact human or chicken tenascin C (20 Wg/ml), pur-
chased from Life Technologies and the Applied Bioligands Corpora-
tion (Winnipeg, Canada), respectively, for 12 h at room temperature,
or with recombinant TNfn3 for 1 h at 37‡C. Wells were washed three
times with PBS and then blocked with 1% BSA in PBS for 1 h at
37‡C. K9L1-Integrin-expressing SW480 cells were harvested from
250 ml tissue culture £asks (Corning) when subcon£uent by adding
2 mM EDTA in PBS and incubating for 20 min at 37‡C. Cells were
washed with DMEM, and the ¢nal cell pellet was resuspended in
serum-free DMEM containing 0.05% BSA. Aliquots of the cell sus-
pension were pretreated by mixing with the relevant peptides for
30 min at 4‡C before addition to the wells. 5U104 cells were applied
to each well, and the plates were incubated for 1^1.5 h at 37‡C in a
humidi¢ed atmosphere with 5% CO2. After washing the wells several
times with PBS, attached cells were ¢xed with pure methanol and
stained with 0.1% (w/v) crystal violet [22]. Excess stain in the wells
was thoroughly washed away with PBS. After air-drying the cells were
solubilized in 1% SDS and quanti¢ed by measuring the absorbance at
570 in a microplate spectrophotometer (SLT).
3. Results and discussion
The phage display technology has proven useful for the
identi¢cation of cell surface receptor binding peptides [23^
25]. By fusing DNA with the minor coat protein pIII gene
of ¢lamentous bacteriophages, phages candidate peptides can
be displayed on the surface of the phages, which can be ap-
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plied to the target of interest. To display three overlapping
peptides of the entire TNfn3 in fusions with the coat protein
pIII of the ¢lamentous bacteriophage fd-tet, we constructed
the recombinant phages fdTENC, fdTEN1, fdTEN2, fdTEN3
according to the strategy shown in Fig. 1. Expression of the
fusion proteins was veri¢ed by SDS-PAGE of the phage pro-
teins (data not shown), and su⁄cient pIII function of all
phage constructs was demonstrated by transduction of TG1
cells.
The phages fdTENC, fdTEN1, fdTEN2, fdTEN3 and fd-tet
were applied separately at equal titers to K9L1-integrin-ex-
pressing SW480 cells, and tested in parallel on mock-trans-
fected control cells, which do not express K9L1-integrins. Both
phages fdTEN1 and fdTEN2, but not fdTEN3, were found to
bind speci¢cally to the K9L1-integrin-expressing SW480 cells
(Fig. 2A), suggesting the location of the K9L1-integrin binding
site in the overlapping region of fdTEN1 and fdTEN2 (Fig.
2B). These data are consistent with the results of a parallel
mutational analysis of acidic amino acid residues in TNfn3 by
Yokosaki and co-workers [18], which identi¢ed the same re-
gion as critical for the binding of tenascin C to K9L1-integrins.
However, since in several independent experiments phage
fdTEN1 adhered better to the K9L1-integrin-expressing cells
than fdTEN2, additional amino acid residues appeared to
be responsible for a strengthening of that binding. After sub-
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Fig. 3. Competitive inhibition of the binding of K9L1-integrin-ex-
pressing SW480 cells to human tenascin C by a synthetic EIDGIEL
peptide. Microtiter plates were coated with intact human tenascin C
(20 Wg/ml) and blocked with BSA. K9L1-Integrin-expressing SW480
cells, either native (white bar) or pretreated with the indicated pep-
tides in equimolar amounts, were applied to the wells, and the
plates were incubated for 1.5 h at 37‡C, 5% CO2. After washing the
wells, attached cells were ¢xed with methanol, stained with crystal
violet, solubilized in 1% SDS and quanti¢ed by measuring the ab-
sorbance at 570 nm. Values are shown as percentage of the un-
treated control cells. The result is the mean of four separate ex-
periments performed in triplicate, error bars represent the standard
deviations.
Fig. 2. Adhesion of fd phages displaying overlapping parts of the
third ¢bronectin type III repeat of tenascin C to transfected SW480
cells. A: Samples of the phages fdTEN-C, fdTEN1, fdTEN2,
fdTEN3 and fd-tet at identical titers were applied to mock-trans-
fected (white bars) or K9L1-integrin-expressing SW480 cells (black
bars) on tissue culture plates blocked with BSA, followed by several
washing steps to achieve speci¢c recovery of the binding phages in
the ¢nal eluate. Afterwards the phage titers in the eluates were esti-
mated. The result is the mean of two separate experiments per-
formed in triplicate for each phage. B: Overlap between the amino
acid sequences displayed by the two phages binding speci¢cally to
K9L1-integrin-expressing cells.
Fig. 1. Strategy for the construction of recombinant phages display-
ing overlapping parts of the third ¢bronectin type III repeat of te-
nascin C. Six oligonucleotides derived from the cDNA encoding hu-
man tenascin C were used to generate three phages displaying
overlapping peptides of 36 amino acids each and a control phage
exposing the entire TNfn3. Oligonucleotide duplexes were obtained
by annealing of the oligonucleotide pairs TEN1A/1B, TEN2A/2B
and TEN3A/3B and ¢lling-in using DNA polymerase I large frag-
ment. The duplexes were cleaved with the restriction endonucleases
ApaLI and NotI and cloned separately in fd phages, resulting in the
phages fdTEN1, fdTEN2 and fdTEN3. Besides, the duplexes TEN1
and TEN2 were joined at the common unique AluI site and sub-
cloned in fd phage. The joined fragments were then excised from
the vector and ligated with duplex TEN3 at the common unique
ScaI site, and the product TENC encoding the entire TNfn3 was
cloned in the phage. Adaptor sequences enabling insertion into
phage DNA are indicated by hooks pointing upwards and down-
wards. Vertical lines represent restriction sites for ApaLI (A), NotI
(N), AluI (U) and ScaI (S).
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traction of the background the di¡erence in the binding capa-
bilities of fdTEN1 and fdTEN2 was about 50% on average.
In accordance with the overlap between TEN1 and TEN2
we ¢rst synthesized the heptapeptide EIDGIEL and studied its
interactions with K9L1-integrin-expressing SW480 cells in com-
petition with human tenascin C. At a concentration of 1 mM,
this peptide was found to inhibit cell adhesion by 50%, where-
as a scrambled control peptide did not in£uence that binding
(Fig. 3). However, its homologous region in chicken tenascin
C (a recombinant fragment of which was used for the muta-
genesis approach by Yokosaki and co-workers [18]) contains a
glutamic acid residue instead of the aspartic acid residue, and
the cells used in both studies express human K9L1-integrins.
Therefore, we con¢rmed that this amino acid exchange is not
critical by performing an analogous competitive cell binding
inhibition experiment on plates coated with native chicken
tenascin C, and obtained virtually the same results as with
the human protein (data not shown). As the two negatively
charged amino acids are exchangeable, only their charge,
which could provide an alternative coordination group for
the integrin to chelate a divalent cation, may play a role in
the binding process. This would be consistent with the as-
sumption that interaction with receptor-bound cations is the
common mechanism for ligand binding to integrins [26].
However, since the peptide EIDGIEL did not show a bind-
ing potency likely to be useful for our purposes and a region
displayed only by phage fdTEN1 appeared to be responsible
for a strengthening of the EIDGIEL-mediated binding, we
extended our investigations to N-terminal amino acids adja-
cent to EIDGIEL. In tenascin C the sequence Pro-Leu-Ala-
Glu-Ile-Asp-Gly (PLAEIDG) is found exposed in a loop be-
tween strands B and C connecting the two L-sheets of TNfn3
[27]. To test the hypothesis that the considerable stronger
binding of fdTEN1 in comparison with fdTEN2 may be due
to the presence of the entire amino acid sequence of this loop,
we synthesized the peptide PLAEIDGIELTY representing the
complete overlap between TEN1 and TEN2 extended by the
remaining three amino acids of the B-C loop of TNfn3. We
also synthesized the peptide KPLAEI to clarify whether the
additional amino acid sequence contains K9L1-integrin binding
activity on its own. The e¡ects of all peptides were directly
compared in a competitive cell binding inhibition experiment
on plates coated with recombinant TNfn3. Pretreatment of
K9L1-integrin-expressing cells with PLAEIDGIELTY at a
concentration of 1 mM resulted in a complete displacement
of the cells from binding to TNfn3, whereas a scrambled
control peptide (IAEYIPLGLETD) did not inhibit that bind-
ing. Furthermore, there were signi¢cant di¡erences between
the blocking e¡ects of EIDGIEL and PLAEIDGIELTY at
all peptide concentrations tested (Fig. 4). Since the di¡erence
in the binding capabilities of phages fdTEN1 and fdTEN2
was reproduced by the peptides PLAEIDGIELTY and
EIDGIEL, it is most likely due to the amino acid sequence
Pro-Leu-Ala. Pretreatment of the cells with KPLAEI did not
in£uence the adhesion of K9L1-integrin-expressing cells to
TNfn3. Thus, the N-terminal part of the B-C loop without
the aspartate and subsequent amino acid residues is unable to
mediate K9L1-integrin binding on its own, suggesting that the
amino acids proline, leucine and alanine function as part of
the recognition site through ful¢llment of conformational re-
quirements for the integrin binding. However, we cannot ex-
clude an unexpected additional contribution of the threonine
and tyrosine residues which, since they are situated far away
from the exposed loop, are unlikely to belong to the cell
adhesion site.
The extended peptide found in this study may prove useful
both for the examination of the functional importance of
K9L1-integrins in vivo and for the development of gene ther-
apy vectors or drugs targeting these integrins.
Integrins often have speci¢c extracellular matrix proteins as
ligands, but many individual integrins can also interact with
cell surface proteins, and most members of the integrin family
can recognize more than one ligand [28]. Therefore, we will
continue to search for short peptides that bind speci¢cally to
K9L1-integrins by biopanning against K9L1-integrin-expressing
SW480 cells using a random peptide phage display library. In
accordance with the aim of our study to identify a novel
targeting ligand for airway epithelia, we will now investigate
the ability of PLAEIDGIEL peptides covalently linked to
polycations to mediate speci¢c gene delivery to K9L1-integ-
rin-expressing cells.
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